Donor Eligibility and Lookback Readiness for Blood and HCT/P Establishments

An operational donor file should explain what was known, who evaluated it, when the decision occurred and which products that decision affected. This guide addresses those connections for blood and HCT/P quality and operations teams. It distinguishes legal requirements from optional record-management practices; it is not a clinical eligibility protocol.

Law — For blood, § 630.10(a) places the collection gate at the collecting establishment: do not collect before determining eligibility or determining that an exception applies. Eligibility includes good health and freedom from transfusion-transmitted infections as determined through the applicable processes; factors adversely affecting donor health or product safety, purity or potency make the donor ineligible.

Law — For HCT/Ps, § 1271.45(b) requires a screening-and-testing-based determination for donors of cells or tissue, except as provided in § 1271.90. For embryos or embryo-derived cells, both the oocyte and semen donors require determinations. Each establishment performing a covered function must comply with the requirements applicable to that function under § 1271.45(d).

Practice (optional) — Give donor eligibility, blood donation suitability and product disposition separate fields or records. A negative test result, a completed interview and a release authorization answer different questions. This guide does not expand specific blood risk factors, physical-assessment limits, donor-type rules, the blood testing panel, additional HCT/P donor-type testing, § 1271.90 exceptions, external standards or reporting obligations under other parts.

Law — Deferral consultation comes before the collection decision

Section 630.10(d)(1) requires consultation of both the local and cumulative deferred-donor records maintained under § 606.160(e)(1) and (2). Only the cumulative record has the collection-site exception: if precollection consultation is not feasible because it cannot be consulted at the collection site, consult it before releasing any blood or component prepared from that collection. This does not postpone consultation of the local record.

Section 606.160(e)(1) requires each location to maintain a record of all donors found ineligible or deferred there. The cumulative record under (e)(2) covers locations under the same license or common management and donors deferred under § 610.41 because donations tested reactive under § 610.40(a)(1) for HIV, HBV or HCV. Establishments other than Source Plasma establishments must also include donors deferred for reactive tests under § 610.40(a)(2) for HTLV or Chagas disease. The cumulative record must be updated at least monthly for newly deferred donors within that scope and revised to remove donors requalified under § 610.41(b).

Law — Interval, interview, physical assessment and acknowledgement

Section 630.10(d)(2)–(4) requires assurance that the interval since the last donation is appropriate, assessment of medical history and a physical assessment. Under § 630.10(e), the medical history interview occurs before collection and assesses good health, relevant infection risks or clinical evidence, and other conditions affecting donor health or product safety, purity or potency. This guide does not supply the individual risk factors or physical-assessment limits.

Under § 630.10(g)(1), obtain proof of identity and a postal address where the donor can be contacted for eight weeks after donation, on the donation day. Under (g)(2), also on the donation day, provide the specified information before each donation and obtain a signature or other documented acknowledgement through established procedures. The acknowledgement must not contain language waiving or appearing to waive legal rights.

The acknowledgement addresses review of educational material; agreement not to donate when the described recipient risk exists; testing of a blood sample; identification as ineligible and notification of the basis for the deferral and the period of deferral when the specified unsuitability or deferral conditions apply; review of donation-procedure risks and hazards; and the opportunity to ask questions and withdraw. Section 630.10(b) also requires understandable educational material concerning relevant infections when donor education is necessary for product safety, including an instruction not to donate when a risk factor is present.

Practice (optional) — Record which deferral record was consulted, the donor identifiers searched, the result and the consultation time. When the cumulative record cannot be consulted onsite, identify the reason and the person assigned to complete that consultation before release. Preserve the interview and acknowledgement versions actually used, rather than attaching today's blank form to an older donation.

Law — Section 630.10(c) requires eligibility determination on the donation day and before collection, with exactly two exceptions. Under (c)(1), for components that cannot be stored for more than 24 hours, eligibility may be determined and the § 610.40 testing sample collected no earlier than two calendar days before the donation day, provided standard operating procedures address those activities.

Law — Under (c)(2), if review finds that the donor's responses to the donor questions before collection were incomplete, a response may be clarified or omitted information required under paragraph (e) obtained within 24 hours of collection, provided standard operating procedures address those activities. This is not permission to collect first and perform the entire eligibility determination later. Its subject is incomplete precollection responses, not every missing record.

Law — Donation suitability is a separate determination under § 630.30(a). Its conditions include no current deferral after record review; results showing good health and procedures protecting donor health; the specified medical-history results; testing under § 610.40 that is negative or nonreactive unless its stated exception applies; and the other applicable requirements of the subchapter. Completing a clarification alone does not establish all those conditions.

Law — Under § 630.30(b)(1), an unsuitable donation must not be released for transfusion or further manufacturing unless it is an autologous donation or an exception is provided in the chapter. Paragraphs (b)(2) and (4) require donor deferral for unsuitability under (a)(1)–(4) and notification under § 630.40. These provisions are not a blanket autologous exemption from other requirements.

Practice (optional) — Treat an unresolved answer, an unconsulted cumulative record, pending testing and an unsuitable donation as distinguishable issues. Record each issue's owner and disposition consequence. One generic ‘pending’ flag makes it difficult to show which condition was resolved and which decision remained open.

Law — Start with relevant medical records

Section 1271.3(n) defines the donor medical history interview as a documented dialog about medical history and relevant social behavior. It is with the living donor when able to participate; otherwise it is with individuals able to provide the information sought. Under § 1271.3(s), relevant medical records include a current interview and a current report of the physical assessment of a cadaveric donor or physical examination of a living donor. They also include, if available, other laboratory results, medical records, coroner and autopsy reports, and information from any source concerning relevant communicable-disease risks.

Section 1271.75(a), except as provided in § 1271.90, requires screening through review of those records for risk factors and clinical evidence of relevant communicable diseases, including HIV, HBV, HCV, human transmissible spongiform encephalopathy including Creutzfeldt-Jakob disease, and Treponema pallidum, plus communicable-disease risks associated with xenotransplantation. Paragraph (d) requires an ineligible determination for a risk factor or clinical evidence covered by its referenced screening provisions, or any communicable-disease risk associated with xenotransplantation.

The abbreviated repeat-donor procedure in § 1271.75(e) applies only when the establishment using it has performed a complete donor screening procedure on that living donor within the previous six months. It must determine and document changes since the previous donation that would make the donor ineligible, including relevant social behavior. It is not simply reuse of an earlier eligibility result.

Law — Preserve specimen timing and testing evidence

Under § 1271.80(a), testing establishments test for the agents specified in § 1271.85, except as provided in § 1271.90; for a donor one month old or younger, the birth mother's specimen is tested instead. The general specimen window in § 1271.80(b) is at recovery or up to seven days before or after. Its exceptions allow collection up to 30 days before recovery for peripheral blood stem/progenitor-cell donors, bone marrow donors if not excepted under § 1271.3(d)(4), and oocyte donors. For repeat semen donors already sampled and tested and subject to § 1271.85(d) retesting, a specimen need not be collected at every donation.

Section 1271.80(c) requires appropriate FDA-licensed, approved or cleared donor screening tests used according to manufacturer instructions, and a laboratory certified for the testing under CLIA or meeting CMS-determined equivalent requirements. Its conditional rule for Chlamydia trachomatis and Neisseria gonorrhea requires FDA-licensed, approved or cleared tests labeled for detection in an asymptomatic, low-prevalence population until appropriate donor screening tests are available. A specifically cadaveric-labeled test replaces a more general test when applicable and available. These are test-selection requirements, not instructions for a universal panel.

Section 1271.85(a) identifies all-donor testing for HIV types 1 and 2, HBV, HCV and Treponema pallidum, subject to § 1271.90. This is not the full panel for every donor type; additional donor-type provisions are outside this guide. Section 1271.80(d)(1) requires an ineligible determination for reactive screening, except a reactive non-treponemal syphilis screen with a negative specific treponemal confirmatory test.

Under § 1271.50, the responsible person determines and documents eligibility from the screening and testing results. Eligibility requires screening showing freedom from relevant risk factors, clinical evidence of infection and xenotransplantation-associated communicable-disease risks, together with negative or nonreactive required testing, except as provided in § 1271.80(d)(1). A pending required result does not supply that completed evidence.

Law — Build the accompanying summary without replacing source records

After determination, § 1271.55(a) requires the HCT/P to be accompanied at all times by a distinct container identification code linking donor, HCT/P and records; an eligible-or-ineligible statement; and a summary of the records used. The code excludes a name, social security number or medical record number except for autologous donations, directed reproductive donations or donations from first- or second-degree blood relatives. Separately, § 1271.55(c) prohibits donor names or other identifying personal information in the accompanying records.

The § 1271.55(b) summary contains the laboratory-qualification statement, a listing and interpretation of the results of all communicable-disease tests performed, and the determining establishment's name and address. For screening-based ineligibility released under § 1271.65(b), it also states the reasons for ineligibility. Practice (optional) — Maintain an index from each summary item to its source report so a reviewer can inspect the evidence rather than rely on a copied status.

Law — Under § 1271.60(a)–(b), an HCT/P awaiting completion of the determination stays in quarantine, clearly identified and easily distinguishable from HCT/Ps available for release and distribution. Under (c), shipment before completion remains in quarantine during shipment. Accompanying records identify the donor, state that the determination is incomplete, and state that implantation, transplantation, infusion or transfer must wait for completion except under (d). Shipment is therefore not the same event as authorization for use.

Law — Section 1271.3(u) defines urgent medical need as no comparable HCT/P being available and the recipient being likely to suffer death or serious morbidity without it. A documented urgent medical need appears in two different pathways. The donor's determination status decides which pathway is relevant.

Practice (optional) — Keep a hand-off packet with the status, legal pathway, label copy, accompanying-record version, receiving contact and communication evidence. If a pending result becomes available while a hand-off is underway, reassess the packet and decision pathway rather than continuing to circulate a stale ‘pending’ description.

Law — Under § 630.10(h), do not collect from a donor found ineligible before collection under the referenced criteria or deferred under the referenced provisions unless the subchapter provides an exception. Defer donors found ineligible and notify them under § 630.40. Section 610.41(a) separately requires future-donation deferral following a reactive screening test under § 610.40(a), subject to these specific exceptions:

• A single occasion of reactivity for anti-HBc or anti-HTLV, types I and II, does not require deferral. Deferral is required if further HBV or HTLV testing under § 610.40(e) is positive, a second licensed, cleared or approved HBV or HTLV screening test under § 610.40(a) on the same donation is reactive, or the specified antibody reactivity occurs on more than one occasion.
• A deferred donor reactive under § 610.40(a) may donate blood or components shipped or used under § 610.40(h)(2)(ii).
• A donor previously showing HBsAg infection evidence under § 610.40(a), (b) and (e) may subsequently donate Source Plasma for preparation of Hepatitis B Immune Globulin (Human) if the current donation is nonreactive for HBsAg and the donor is otherwise eligible.
• An otherwise eligible deferred donor reactive for anti-HBc or evidence of HTLV, types I and II, infection may donate Source Plasma.
• A deferred donor reactive for a relevant transfusion-transmitted infection under § 610.40(a) may serve as an autologous donor under § 610.40(d).

Law — Under § 610.41(b), requalification uses a method or process found acceptable by FDA; the requalified donor is considered no longer deferred. Under § 610.41(c), reactive required HIV or HCV screening, or awareness of other reliable results or information indicating HIV or HCV infection, triggers compliance with §§ 610.46 and 610.47. See Lookback for those clocks and subsequent steps.

Practice (optional) — Send the lookback owner the donor code, triggering report or information, date and time received, linked earlier donations, current product locations, distribution records and known consignees. Identify a named sender and recipient and record acknowledgement. Keep donor notification, deferral-record maintenance and lookback work distinguishable even when the same evidence initiates all three.

Practice (optional) — Quality-event intake, not an automatic legal conclusion

Use a quality-event intake when product has been released or shipped without a completed determination. First establish whether the event followed a documented quarantine-shipment or applicable exception pathway, or whether an expected control was missed. An incomplete HCT/P determination is not, by itself, proof that a quarantine shipment was improper. Record what actually occurred before assigning a cause or disposition.

1. Assign named people: an investigator, a product-status owner, an evidence-retrieval owner and a decision approver. Record their individual assignments, not merely ‘Quality’ or ‘Operations.’
2. Reconstruct the sequence: collection or recovery, assessment, result availability, determination, status changes, shipment, receipt and any use. Distinguish event time from the time a later entry was made.
3. Scope affected material through donor, donation, HCT/P or component identifiers and actual distribution records. Record what was located, what remains uncertain and who is resolving each uncertainty.
4. Preserve the original records, label versions, messages and relevant system history. Obtain missing facts transparently; do not make a late entry look contemporaneous.
5. Document the disposition decision, rationale, communications and follow-up owners. Check whether the underlying problem was a missing result, missing decision, wrong status, failed hand-off or misleading record presentation.

Practice (optional) — A useful closure explains both the immediate product decision and why the record chain failed. If an authorized pathway was followed, record that conclusion rather than manufacturing a compliance failure. Reporting obligations under other regulatory parts require a separate assessment and are outside this guide.

Practice exercise — Entirely fictional. Donor D-0000-FICT presents on 2026-09-08; donation B-0000-FICT links all resulting components. The site's existing procedures address § 630.10(c)(2) clarification. The cumulative record cannot be consulted at this collection site, but the local record can. Staff record the precollection assessment and determination. Later review finds one incomplete precollection medical-history response—not an interview that was deliberately postponed.

Practice exercise — The lesson is the sequence, not a clinical answer key. The clarification occurs within the specific § 630.10(c)(2) window, while the cumulative consultation follows its separate § 630.10(d)(1) exception before release. Neither exception substitutes for the other. If the response could not be clarified within that provision's conditions, this example's resolution would not apply; quality would need a separate assessment without relabeling a late clarification as timely.

Practice exercise — Entirely fictional. Living donor H-0000-FICT and HCT/P T-0000-FICT are linked to screening, specimen and recovery records. One required testing result remains pending. Rena Moss-FICT is the establishment's authorized, trained and qualified responsible person. These dates illustrate records and hand-offs, not product viability or clinical treatment instructions.

Practice exercise — The urgent-use packet did not declare this donor eligible while testing was pending. It preserved the incomplete status and the basis for the § 1271.60(d) pathway, then closed the determination after use. Contrast an already-ineligible donor: § 1271.65(b) would require its own limited-use basis, Biohazard and warning labeling, § 1271.55 records and documentation of physician notice of screening and testing results. A ‘pending’ label would misdescribe that different case.

Law — Section 1271.55(d) requires retention of testing results and interpretation with laboratory names and addresses, screening results and interpretation, and the determination with the responsible person's name and determination date. Records must be accurate, indelible and legible. Donor identity and relevant medical records must be in English or retained with an English translation and a translator's authenticity statement specifically identifying the document. Required records must be available for authorized FDA inspection or request; readily retrievable electronic records at another location count as retained.

Law — Section 1271.270(a) requires concurrent records identifying the person performing the work and entry dates, with enough detail to reconstruct the work and relate it to the HCT/P. Under (c), electronic records, original paper and true copies are permitted; equipment needed for availability and legibility must be readily available, and electronic records must be backed up.

Practice (optional) — Rehearse two retrievals: donor-to-all-products and product-to-donor-decision. Include original assessments, source results, interpretation, decision identity/date, status changes, labels, shipments and communications. Ask a colleague unfamiliar with the case to identify which facts were known at each decision point. A tidy final summary is insufficient for this exercise if it obscures the original sequence.

Practice (optional) — Evaluate a proposed record system with fictional cases, not product promises. Ask the supplier to show the records and exports supporting each answer, including what requires manual work.

• Can separate donor eligibility, donation suitability, quarantine, shipment and disposition decisions retain their own people, dates and evidence?
• Can local and cumulative deferral consultations be distinguished, including an unresolved pre-release consultation?
• Can a late clarification preserve the original response and show collection, discovery and clarification times?
• Can pending testing, completed determinations and already-ineligible donors have visibly different records and hand-off packets?
• Can the actual labels, accompanying records and physician communications be retrieved by product identifier?
• Can retention schedules use the different blood and HCT/P trigger dates without silently defaulting everything to creation date?
• Can records remain legible, linked and retrievable after export, migration or restoration from backup?
• Can named investigators reconstruct a fictional unexpected shipment without relying on undocumented staff memory?